Trial Profile

Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ANPD 001 (Primary)
Indications Parkinson's disease
Focus Adverse reactions; First in man
Acronyms ASPERO; ASPIRO
Sponsors Aspen Neuroscience

Most Recent Events

09 Jun 2025 Results published in the Media Release
09 Jun 2025 According to an Aspen Neuroscience media release, the company announced Dr. Bratt-Leal's presentation will cover data for the first four patients of the ASPIRO Study*, a Phase 1/2a trial of the company's iPSC-derived autologous cell therapy (ANPD001) at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, to be held in Hong Kong June 11-14.
07 May 2025 Results from the first three patients dosed in the ASPIRO Phase 1/2a trial presented in the Aspen Neuroscience Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com